BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical GroupGlobeNewsWire · 5 days ago
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered LivesGlobeNewsWire · Oct 13, 2026
HWG Holdings LP Buys New Stake in Brainsway Ltd. Sponsored ADR $BWAYDefense World · Oct 8, 2026
Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)Defense World · Oct 5, 2026
Brainsway (NASDAQ:BWAY) Shares Gap Down – What’s Next?Defense World · Sep 24, 2026
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™GlobeNewsWire · Sep 8, 2026BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | $0.10 | $0.14 | Beat |
| May 13, 2026 | $0.05 | $0.12 | Beat |
| Mar 11, 2026 | $0.06 | $0.14 | Beat |
| Nov 11, 2025 | $0.05 | $0.04 | Miss |
| Aug 13, 2025 | $0.04 | $0.05 | Beat |
| May 13, 2025 | $0.01 | $0.02 | Beat |